propafenone has been researched along with Constipation in 1 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Constipation: Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this randomized, double-blind, placebo-controlled clinical trial was to test the efficacy and safety of a new sustained-release preparation of the antiarrhythmic drug propafenone (propafenone SR) in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation (AF)." | 9.10 | Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. ( Carlson, M; Fava, G; Page, RL; Pritchett, EL; Undesser, K, 2003) |
| "The objective of this randomized, double-blind, placebo-controlled clinical trial was to test the efficacy and safety of a new sustained-release preparation of the antiarrhythmic drug propafenone (propafenone SR) in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation (AF)." | 5.10 | Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. ( Carlson, M; Fava, G; Page, RL; Pritchett, EL; Undesser, K, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pritchett, EL | 1 |
| Page, RL | 1 |
| Carlson, M | 1 |
| Undesser, K | 1 |
| Fava, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation[NCT02145546] | Phase 4 | 600 participants (Anticipated) | Interventional | 2014-05-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for propafenone and Constipation
| Article | Year |
|---|---|
Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; C | 2003 |